Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma скачать в хорошем качестве

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Prof Richard S Finn speaks to ecancer about the primary results from the phase 3 LEAP-002 study evaluating the efficacy and safety of lenvatinib plus pembrolizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma (aHCC). Dual primary endpoints OS and PFS were assessed using the stratified log-rank test. ORR was a key secondary endpoint. The protocol specified 2 interim analyses (IAs) and a final analysis (FA) for OS. LEAP-002 primary endpoints of OS (at FA) and PFS (at IA1) did not meet pre-specified statistical significance. The combination of lenvatinib + pembrolizumab achieved the longest median OS ever reported in first-line HCC phase 3 studies (21.2 months) with no new safety signals observed.  The median OS of 19.0 months with lenvatinib monotherapy supports its role as a standard of care in first-line aHCC.